Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Xtent, Inc.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.
The approval of China's second CAR-T therapy has come amid reimbursement challenges, despite the pricing of its direct competitor being much lower than in the US. Chinese developers are pinning their hopes on rapid domestic market expansion via commercial insurance tie-ups as other CAR-Ts move through local development.
Given its ever-growing role as a critical region for the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
- Implantable Devices